2023 World Conference on Lung Cancer (Posters)-EP12.01. Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib

EP12.01. Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib - PDF(Abstract)

Back to course

Pdf Summary

This abstract describes a study conducted to investigate the molecular markers of resistance in the first-line treatment of non-small cell lung cancer (NSCLC) with EGFR positive mutation using a specific tyrosine kinase inhibitor called Aumolertinib. The researchers aimed to identify molecular markers that can predict the prognosis and response to treatment with Aumolertinib.<br /><br />The introduction provides background information on third-generation EGFR tyrosine kinase inhibitors and their efficacy in improving overall survival and progression-free survival in NSCLC patients with EGFR mutations. However, only about two-thirds of patients respond to these inhibitors, suggesting the existence of unknown mechanisms of resistance. Previous cohort analysis identified several molecular markers, such as T790M/EGFR MAF ratio, FGFR1 amplification, MET amplification, and various gene mutations, that may be associated with drug resistance to third-generation EGFR tyrosine kinase inhibitors.<br /><br />The methods section outlines the study design, which includes 30 eligible NSCLC patients who will receive Aumolertinib as their first-line therapy. The patients will provide blood or tumor tissue samples before, during, and after disease progression. Complete clinical and pathological data will also be collected. Next-generation sequencing will be performed to analyze gene mutations, tumor mutation burden, and PD-L1 expression. The Cox single-factor and progression-free survival analysis will be used to determine the predictive value of these molecular markers independent of tumor mutation burden and PD-L1 expression.<br /><br />In summary, this study aims to validate the predictive value of specific molecular markers for resistance to Aumolertinib in the first-line treatment of NSCLC patients with EGFR-positive mutations. The findings of this study may ultimately contribute to personalized treatment strategies and improve the prognosis of NSCLC patients.

Asset Subtitle

Jian Chun Duan

Meta Tag

Speaker Jian Chun Duan

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

molecular markers

resistance

first-line treatment

non-small cell lung cancer

NSCLC

EGFR positive mutation

tyrosine kinase inhibitor

Aumolertinib

prognosis

response to treatment